Natural-disaster risk in research and clinical-trial locations
First written in FY2016. 8 of 11 entries say "Restated". Latest entry: FY2023-Q3.
OncoTherapy Science moved to the "Worse" side of this theme in 2018.
3 other companies' latest entry also says "Restated".
- FY2023-Q3RestatedAnnual report
「In addition, although the specific impact of COVID-19 on the company's group business is currently minor, it is impossible to foresee when the event will end, making it difficult to reasonably predict what impact it may have going forward」
Regarding COVID-19, the company continues to disclose the risk that, while its specific impact is currently minor, the timing of its end and its future impact cannot be predicted. - FY2023-Q1RestatedAnnual report
「In addition, although the specific impact of COVID-19 on the company's group business is currently minor, it is impossible to foresee when the event will end, making it difficult to reasonably predict what impact it may have going forward」
Regarding COVID-19, the company continues to disclose the risk that, while its specific impact on the business is currently minor, the timing of its end and its future impact cannot be predicted. - FY2022-Q3RestatedAnnual report
「In addition, although the specific impact of COVID-19 on the company's group business is currently minor, it is impossible to foresee when the event will end, making it difficult to reasonably predict what impact it may have going forward」
Regarding COVID-19, the company continues to disclose the risk that, while its specific impact on the business is currently minor, the timing of its end and its future impact cannot be predicted. - FY2022-Q1RestatedAnnual report
「In addition, although the specific impact of COVID-19 on the company's group business is currently minor, it is impossible to foresee when the event will end, making it difficult to reasonably predict what impact it may have going forward」
Regarding COVID-19, the company continues to disclose the risk that, while its specific impact on the business is currently minor, the timing of its end and its future impact cannot be predicted. - FY2021-Q3RestatedAnnual report
「In addition, although the specific impact of COVID-19 on the company's group business is currently minor, it is impossible to foresee when the event will end, making it difficult to reasonably predict what impact it may have going forward」
Regarding COVID-19, the company continues to disclose the risk that, while its specific impact on the business is currently minor, the timing of its end and its future impact cannot be predicted. - FY2021-Q2RestatedAnnual report
「In addition, although the specific impact of COVID-19 on the company's group business is currently minor, it is impossible to foresee when the event will end, making it difficult to reasonably predict what impact it may have going forward」
Regarding COVID-19, the company continues to disclose the risk that, while its specific impact on the business is currently minor, the timing of its end and its future impact cannot be predicted. - FY2021-Q1RestatedAnnual report
「In addition, although the specific impact of COVID-19 on the company's group business is currently minor, it is impossible to foresee when the event will end, making it difficult to reasonably predict what impact it may have going forward」
Regarding COVID-19, the company continues to disclose the risk that, while its specific impact on the business is currently minor, the timing of its end and its future impact cannot be predicted. - FY2020WorsenedAnnual report
「If a large-scale natural disaster such as an earthquake or an infectious disease such as COVID-19 occurs at any of the company's group's business sites or in a region where research or clinical trials involving the company's group are being conducted or prepared, and the group's business activities or clinical trials are halted due to damage to facilities or the loss of infrastructure functions, the business strategy and operating results of the company's group may be affected.」
In addition to natural disasters, the company explicitly identified the risk that infectious diseases such as COVID-19 could halt business activities and clinical trials, expanding the scope of the risk. - FY2018WorsenedAnnual report
「If a large-scale natural disaster such as an earthquake occurs at any of the company's group's business sites or in a region where research or clinical trials involving the company's group are being conducted or prepared」
The scope of natural-disaster risk explicitly expanded beyond research and clinical trial regions to include business sites and business activities generally. - FY2017RestatedAnnual report
「If a large-scale natural disaster such as an earthquake occurs in a region where research or clinical trials are being conducted or prepared, and research or clinical trials are halted due to damage to facilities or the loss of infrastructure functions, the business strategy and operating results of the company's group may be affected.」
The risk of natural disasters and facility or infrastructure outages in research and clinical trial regions continues. - FY2016First statedAnnual report
「If a large-scale natural disaster such as an earthquake occurs in a region where research or clinical trials are being conducted or prepared, and research or clinical trials are halted due to damage to facilities or the loss of infrastructure functions, the business strategy and operating results of the company's group may be affected.」
The company identifies geographic concentration in research and clinical trials and infrastructure outages as external risks.